UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                 SCHEDULE 13G/A
                                (AMENDMENT NO. 7)


                    UNDER THE SECURITIES EXCHANGE ACT OF 1934


                         MANHATTAN PHARMACEUTICALS, INC.


                    Common Stock, par value $0.001 per share
                         (Title of Class of Securities)

                                    563118207
                                  CUSIP Number

                                December 31, 2005
                      (Date of Event which Requires Filing
                               of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

                                |_| Rule 13d-1(b)
                                |X| Rule 13d-1(c)
                                |_| Rule 13d-1(d)


*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).

                          Continued on following pages
                                Page 1 of 5 Pages





                                  SCHEDULE 13G

CUSIP No. 563118207
                                                                     Page 2 of 5


1        Names of Reporting Persons
         I.R.S. Identification Nos. of above persons (entities only)

                           LINDSAY A. ROSENWALD, M.D.

2        Check the Appropriate Box If a Member of a Group *

                                                     a.     |_|
                                                     b.     |_|

3        SEC Use Only

4        Citizenship or Place of Organization

                  UNITED STATES

                            5             Sole Voting Power
Number of                                 4,023,070
  Shares
Beneficially                6             Shared Voting Power
  Owned By                                189
    Each
Reporting                   7             Sole Dispositive Power
    Person                                4,023,070
    With
                            8             Shared Dispositive Power
                                          189

9        Aggregate Amount Beneficially Owned by Each Reporting Person

                                    4,023,259

10       Check Box If the Aggregate Amount in Row (9) Excludes Certain
         Shares *

                                       |_|

11       Percent of Class Represented By Amount in Row (9)

                                      6.6%

12       Type of Reporting Person *

                                       IN

* see instructions before filling out





ITEM 1(A)         NAME OF ISSUER:

                  Manhattan Pharmaceuticals, Inc. (the "Issuer")

ITEM 1(B)         ADDRESS OF THE ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

                       810 Seventh Avenue
                       New York, NY  10019

ITEM 2(A)         NAME OF PERSON FILING:

                  Lindsay A. Rosenwald, M.D. (the "Reporting Person").

ITEM 2(B)         ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

                       c/o Paramount BioCapital Investments, LLC
                       787 Seventh Avenue, 48th Floor
                       New York, NY 10036


ITEM 2(C)         CITIZENSHIP:
                  The Reporting Person is a citizen of the United States.

ITEM 2(D)         TITLE OF CLASS OF SECURITIES:

                  Common Stock (the "Shares").

ITEM 2(E)         CUSIP NUMBER:

                  563118207


ITEM 3.           IF THIS  STATEMENT IS FILED  PURSUANT TO RULE  13D-1(B),
                  OR 13D-2(B) OR (C),  CHECK  WHETHER THE PERSON FILING IS A:

                  This Item 3 is not applicable.

ITEM 4.           OWNERSHIP:

ITEM 4(A)         AMOUNT BENEFICIALLY OWNED:

                  Reporting Person beneficially owns 4,023,259 Shares,
                  consisting of (i) 3,183,421 Shares held directly by the
                  Reporting Person; (ii) 839,649 Shares to be held directly by
                  the Reporting Person upon the exercise of warrants; (iii) 38
                  Shares held by June Street Company of which the Reporting
                  Person is the sole shareholder; (iv) 38 Shares held by
                  Huntington Street Company of which the Reporting Person is the
                  sole shareholder; (v) 80 Shares held by the Reporting Person's
                  wife, over which Shares the Reporting Person may be deemed to
                  have sole voting and dispositive power, although the Reporting
                  Person disclaims beneficial ownership of such Shares except
                  with regard to his pecuniary interest therein, if any; and
                  (vi) 33 Shares held by the Reporting Person's minor children,
                  over which Shares the Reporting Person may be deemed to have
                  sole voting and dispositive power, although the Reporting
                  Person disclaims beneficial ownership of such Shares except
                  with regard to his pecuniary interest therein, if any.





ITEM 4(B)         PERCENT OF CLASS:

                  See Item 11 of the cover page.


ITEM 4(C)         NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:


                                                                             
         (i)      Sole power to vote or direct the vote:                        Please see Item 5 of the cover
                                                                                page.
         (ii)     Shared power to vote or to direct the vote                    Please see Item 6 of the cover
                                                                                page.
         (iii)    Sole power to dispose or to direct the disposition of         Please see Item 7 of the cover
                                                                                page.
         (iv)     Shared power to dispose or to direct the disposition of       Please see Item 8 of the cover
                                                                                page.


ITEM 5.           OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

                  This Item 5 is not applicable.

ITEM 6.           OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
                  PERSON:

                  See Item 4 Above.

ITEM 7.           IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
                  ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT
                  HOLDING COMPANY:

                  This Item 7 is not applicable.

ITEM 8.           IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

                  This Item 8 is not applicable.

ITEM 9.           NOTICE OF DISSOLUTION OF GROUP:

                  This Item 9 is not applicable.

ITEM 10.          CERTIFICATION:

                  By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having such purpose or
effect.





                                   SIGNATURES


                  After reasonable inquiry and to the best of my knowledge and
belief, the undersigned certifies that the information set forth in this
statement is true, complete and correct.

                                                 February 10, 2006


                                                 --------------------------
                                                 Lindsay A. Rosenwald, M.D.